MELBOURNE, Australia, July 18, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 30 June 2024 (Q2 2024).
Q2 2024 Financial Performance and Guidance Upgrade
The Company reports unaudited total revenue of approximately US$124M1 (AU$189M) primarily generated from sales of Telix’s prostate cancer imaging product Illuccix®. This represents an increase of 55% on the prior corresponding quarter (Q2 2023: US$80M or AU$120M) and an increase of 8% on the previous quarter (Q1 2024: US$115M or AU$175M). Revenue generated from sales of Illuccix® in the United States (U.S.) was approximately US$121M (AU$184M, Q2 2023: US$78M or AU$116M).
On the basis of these results, the Company has upgraded revenue guidance for FY2024 which is now expected to be in the range of US$490M to US$510M (AU$745M to AU$776M at current exchange rates). This represents an approximate increase of 48% to 54% on 2023 revenue. Prior guidance was ranged at US$445M to US$465M2 (AU$675M to AU$705M).
Dr Christian Behrenbruch, Managing Director and Group Chief Executive Officer said, “We have continued to deliver excellent quarterly growth in both revenue and dose volume sales of Illuccix. We have leveraged our unrivalled scheduling flexibility and clinical differentiation, to increase our market share and minimise the impact of new entrants.”
Revenue guidance is based on approved products in jurisdictions with a marketing authorisation3. Telix reaffirms guidance for R&D expenditure, which remains at an expected 40-50% increase compared with 2023, funded by earnings.
The above guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are included below as a footnote4.
The Company will release its interim report and Appendix 4D for the six months ended 30 June 2024 on 22 August 2024.
Q2 2024 Operational Highlights
Telix continued to progress its extensive theranostic pipeline during the quarter. Highlights include positive data from prostate cancer therapy programs:
Telix is progressing multiple marketing authorisation applications across its precision medicine (diagnostic) portfolio, including:
Subsequent to the end of Q2 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) announced proposed changes for the Hospital Outpatient Prospective Payment System (OPPS) rule, which would improve payments to Medicare patients for diagnostic radiopharmaceuticals in the U.S., including Illuccix® and future Telix diagnostic products, if approved10. Telix welcomes the proposal to keep the payment for the diagnostic radiopharmaceuticals separate from the nuclear medicine test (scan) after transitional pass-through payment status expires, which will facilitate continued patient access11. The proposal is now in a 60-day comment period, with a final rule to be issued in early November 2024 and take effect 1 January 2025.
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).
Telix’s lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)12, by the Australian Therapeutic Goods Administration (TGA) 13, and by Health Canada14. No other Telix product has received a marketing authorisation in any jurisdiction.
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn.
Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com
This announcement has been authorised for release by the Board of Telix Pharmaceuticals Limited.
Legal Notices
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. The information contained in this announcement is subject to change without notification.
This announcement may contain forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the ASX or on our website.
To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.
©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Illuccix®, Pixclara™8 and Zircaix®8 names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
1 Conversion to AUD$ is at an average exchange rate realised during Q2 2024 of AUD$1 = US$0.658
2 Telix ASX disclosures 22 February and 17 April 2024.
3 Illuccix® has received a marketing authorisation in Australia, Canada and the U.S.
4 Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix’s ability to protect its patents and other intellectual property.
5 Imaging of prostate-specific membrane antigen with positron emission tomography.
6 Telix ASX disclosure 27 May 2024.
7 Prescription Drug User Fee Act.
8 Brand name subject to final regulatory approval.
9 Telix ASX disclosure 3 June 2024.
10 CMS Press Release 10 July 2024.
11 Telix ASX disclosure 11 July 2024.
12 Telix ASX disclosure 20 December 2021.
13 Telix ASX disclosure 2 November 2021.
14 Telix ASX disclosure 14 October 2022.
PUNE, India, July 19, 2024 /PRNewswire/ -- Wearable Technology Market size is expected to grow…
PUNE, India, July 19, 2024 /PRNewswire/ -- Printed & Flexible Sensors Market size was valued…
Company awarded government project agreement to onshore key pharmaceutical supply chains, alongside strategic investment from…
Company Now Servicing Over 9 Million Veterans NEW YORK, July 19, 2024 /PRNewswire/ -- Legacy,…
CHICAGO, IL / ACCESSWIRE / July 19, 2024 / Cosmos Health Inc. ("Cosmos Health" or…
AUSTIN, TX / ACCESSWIRE / July 19, 2024 / Medicare officially announces LCD changes that…